ALVOTECH

NASDAQ: ALVO (Alvotech)

Kemas kini terakhir: 21 Nov, 1:28PM

5.22

0.16 (3.16%)

Penutupan Terdahulu 5.06
Buka 5.12
Jumlah Dagangan 204,863
Purata Dagangan (3B) 500,557
Modal Pasaran 1,626,557,952
Harga / Pendapatan (P/E TTM) 22.70
Harga / Pendapatan (P/E Ke hadapan) 9.52
Harga / Jualan (P/S) 2.33
Julat 52 Minggu
4.70 (-9%) — 13.70 (162%)
Tarikh Pendapatan 12 Nov 2025
Margin Keuntungan 16.42%
Margin Operasi (TTM) 7.97%
EPS Cair (TTM) 0.370
Pertumbuhan Hasil Suku Tahunan (YOY) 260.00%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -65.50%
Nisbah Semasa (MRQ) 1.73
Aliran Tunai Operasi (OCF TTM) -148.89 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -216.76 M
Pulangan Atas Aset (ROA TTM) 7.02%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menaik Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menaik Bercampur
Stok Alvotech Menurun Menurun

AISkor Stockmoo

1.3
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.0
Purata Bergerak Teknikal 3.5
Osilator Teknikal -2.5
Purata 1.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALVO 2 B - 22.70 -
LNTH 4 B - 24.85 3.18
KNSA 3 B - 90.20 6.03
BCRX 1 B - - 56.59
HROW 1 B - - 32.91
ETON 442 M - - 17.82

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 63.44%
% Dimiliki oleh Institusi 6.44%

Pemilikan

Nama Tarikh Syer Dipegang
Lodbrok Capital Llp 30 Sep 2025 181,587
Julat 52 Minggu
4.70 (-9%) — 13.70 (162%)
Julat Harga Sasaran
8.00 (53%) — 14.00 (168%)
Tinggi 14.00 (Morgan Stanley, 168.20%) Beli
Median 10.00 (91.57%)
Rendah 8.00 (Deutsche Bank, 53.26%) Pegang
Purata 10.67 (104.41%)
Jumlah 2 Beli, 1 Pegang
Harga Purata @ Panggilan 6.15
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
UBS 18 Nov 2025 10.00 (91.57%) Beli 5.11
Deutsche Bank 04 Nov 2025 8.00 (53.26%) Pegang 4.83
23 Sep 2025 14.00 (168.20%) Beli 8.70
Morgan Stanley 14 Oct 2025 14.00 (168.20%) Beli 8.50

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
24 Nov 2025 Pengumuman Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
24 Nov 2025 Pengumuman Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
20 Nov 2025 Pengumuman Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20 Nov 2025 Pengumuman Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
12 Nov 2025 Pengumuman Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
12 Nov 2025 Pengumuman Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
10 Nov 2025 Pengumuman UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)         
10 Nov 2025 Pengumuman UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
06 Nov 2025 Pengumuman Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06 Nov 2025 Pengumuman Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
04 Nov 2025 Pengumuman Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
04 Nov 2025 Pengumuman Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
02 Nov 2025 Pengumuman Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
02 Nov 2025 Pengumuman Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
22 Oct 2025 Pengumuman Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22 Oct 2025 Pengumuman Alvotech Announces Changes in Global Business Development and Commercial Operations Team
06 Oct 2025 Pengumuman Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
06 Oct 2025 Pengumuman European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06 Oct 2025 Pengumuman European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
22 Sep 2025 Pengumuman European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 Pengumuman European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 Pengumuman European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22 Sep 2025 Pengumuman European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
19 Sep 2025 Pengumuman Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
19 Sep 2025 Pengumuman Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda